Investor Group Says China's Sinovac Worth 75% More than Management's Offer
publication date: Sep 2, 2016
Heng Ren Investments of Boston believes Sinovac's management should raise its privatization offer for Sinovac by 75%: from $6.18 per share to $10.84. Just before management made its offer, Heng Ren says, Sinovac received China approval for its Hand, Foot and Mouth vaccine, a product with $400 million in potential revenues. Given that Sinovac. which is based in Beijing, posted $67 million in sales last year, the effect on Sinovac could be substantial. Heng Ren specializes in "orphan" China companies listed in the US and has a position in Sinovac. More details....
Stock Symbol: (NSDQ: SVA)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.